Disability and survival of multiple sclerosis in Saskatoon, Saskatchewan
- PMID: 20169770
- DOI: 10.1017/s0317167100009616
Disability and survival of multiple sclerosis in Saskatoon, Saskatchewan
Abstract
Background: A population-based prevalent group of 150 clinical definite patients ascertained on 1 January 1977, in Saskatoon, Saskatchewan, was followed for 30 years.
Objectives: To outline the clinical characteristics, determine the levels of disability at 15, 25, 35, 40, and 45 years after onset, to estimate the survival after onset and life expectancy.
Methods: Clinical records were maintained, and the cohort reviewed each decade for 30 years. The disability levels according to the Kurtzke Extended Disability Status Scale were recorded and survival times were estimated. SPSS and Kaplan-Meier methods were used for analysis.
Results: On prevalence day, 1 January 1977, there were 48 (32%) men and 102 (68%) women, with an average age of onset of 32.2 +/- 10 years and 28.4 +/- 8.6 years. The average duration of disease was 15.7 years. On 1 January 2007, 39 (26%) patients were living, 105 (70%) deceased, and 6 (4%) were missing The disability levels recorded in 1977 and 2007, at 15 and 45 years after onset, were mild (EDSS < or = 2.5), 33.3% and 8.0%; moderate (EDSS3-5.5), 17.3% and 2.7%; severe (EDSS6-7.5), 6.6% and 4.7%; maximum (EDSS8-9.5), 22.7% and 10.7%. The median survival time after onset was 33 (95% CI: 27.3-38.6) years for men and 38 (95% CI: 34.1-41.9) years for women. The median duration of life was 68.9 years for men and 69.5 years for women, and a decreased life expectancy of 7.7 and 12.8 years.
Conclusions: Multiple sclerosis is a progressive neurological disorder and long-term survival is associated with moderate to severe disability and decreased life expectancy.
Similar articles
-
Incidence and prevalence of multiple sclerosis in Saskatoon, Saskatchewan.Neurology. 2007 Sep 18;69(12):1224-9. doi: 10.1212/01.wnl.0000276991.13764.77. Neurology. 2007. PMID: 17875910
-
Disability profile of MS did not change over 10 years in a population-based prevalence cohort.Neurology. 2004 Feb 24;62(4):601-6. doi: 10.1212/wnl.62.4.601. Neurology. 2004. PMID: 14981177 Review.
-
The natural history of multiple sclerosis: a regional study with some longitudinal data.J Neurol Neurosurg Psychiatry. 1992 May;55(5):341-6. doi: 10.1136/jnnp.55.5.341. J Neurol Neurosurg Psychiatry. 1992. PMID: 1602305 Free PMC article.
-
The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset.J Neurol. 2015 May;262(5):1148-63. doi: 10.1007/s00415-015-7674-y. Epub 2015 Feb 26. J Neurol. 2015. PMID: 25712541
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
Cited by
-
Immune mediated diseases and immune modulation in the neurocritical care unit.Neurotherapeutics. 2012 Jan;9(1):99-123. doi: 10.1007/s13311-011-0096-3. Neurotherapeutics. 2012. PMID: 22161307 Free PMC article. Review.
-
Potential biological contributers to the sex difference in multiple sclerosis progression.Front Immunol. 2023 Apr 14;14:1175874. doi: 10.3389/fimmu.2023.1175874. eCollection 2023. Front Immunol. 2023. PMID: 37122747 Free PMC article.
-
Predictors of Mortality in Veterans with Multiple Sclerosis in an Outpatient Clinic Setting.Int J MS Care. 2017 Sep-Oct;19(5):265-273. doi: 10.7224/1537-2073.2016-067. Int J MS Care. 2017. PMID: 29070968 Free PMC article.
-
Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.PLoS One. 2015 Jul 6;10(7):e0132033. doi: 10.1371/journal.pone.0132033. eCollection 2015. PLoS One. 2015. PMID: 26148099 Free PMC article.
-
The prevalence of familial multiple sclerosis in saskatoon, Saskatchewan.Mult Scler Int. 2014;2014:545080. doi: 10.1155/2014/545080. Epub 2014 Feb 3. Mult Scler Int. 2014. PMID: 24672728 Free PMC article.